Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge

被引:47
|
作者
Manohar, Sandhya [1 ]
Ghamrawi, Ranine [1 ]
Chengappa, Madhuri [5 ]
Goksu, Busra N. Bacik [6 ]
Kottschade, Lisa [2 ]
Finnes, Heidi [3 ]
Dronca, Roxana [7 ]
Leventakos, Konstantinos [2 ]
Herrmann, Joerg [4 ]
Herrmann, Sandra M. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55902 USA
[2] Mayo Clin, Dept Med Oncol, Rochester, MN 55902 USA
[3] Mayo Clin, Dept Pharm, Rochester, MN 55902 USA
[4] Mayo Clin, Dept Cardiol, Rochester, MN 55902 USA
[5] Nazareth Hosp, Dept Internal Med, Philadelphia, PA USA
[6] Univ Texas Southwestern, Dept Psychiat, Dallas, TX USA
[7] Mayo Clin, Dept Med Oncol, Jacksonville, FL 32224 USA
来源
KIDNEY360 | 2020年 / 1卷 / 01期
关键词
Acute Kidney Injury and ICU Nephrology; Acute Interstitial Nephritis; Acute Kidney Injury; Biopsy; Cohort Studies; Creatinine; Immune check point-rechallenge; Immune checkpoint inhibitors; Immune-related adverse event; Immunotherapy; Kidney Function Tests; Pneumonia; Prednisone; Proton Pump Inhibitors; COMBINED NIVOLUMAB; RENAL-FUNCTION; ASSOCIATION; IPILIMUMAB; RECOVERY; FEATURES;
D O I
10.34067/KID.0000152019
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background The objective of this case cohort study was to describe our experience in the care of patients with immune checkpoint inhibitor-related acute interstitial nephritis (ICI-AIN) including rechallenge. Methods A descriptive case series of patients that received an ICI and had an AKI (defined as a >= 1.5-fold increase in serum creatinine) as an immune-related adverse event (irAE), with biopsy-proven or clinically suspected ICI-AIN from January 1, 2014 to December 1, 2018 at Mayo Clinic, Rochester. We studied details regarding diagnosis, clinical course, management, and outcomes of rechallenge of immunotherapy. Complete response (CR) was defined as return of kidney function back to baseline or < 0.3 mg/dl above baseline creatinine; partial response (PR) was defined as creatinine > 0.3 mg/dl from baseline, but less than twofold above the baseline by the end of steroid course. Results A total of 14 cases of biopsy-proven (35%) or clinically suspected (65%) ICI-AIN was identified. All patients had their ICI withheld and 12 patients received steroids. Steroid regimens were highly variable. The starting equivalent dose of prednisone was higher in those that had a CR versus a PR (median 0.77 mg/kg versus 0.66 mg/kg). Proton pump inhibitors (PPIs) were used in 11 patients and were stopped in eight (73%) patients at the time of the AKI event. A CR was seen in five (63%) of the eight patients who discontinued PPIs. Rechallenge was attempted in four of the 14 patients: three were successful with no recurrence of AKI, but one patient had recurrent AKI and fatal pneumonitis. Conclusions Careful review, withholding ICI and concomitant known AIN-inducing medications, along with prompt initial steroid management were the key in complete renal kidney recovery. A kidney biopsy should be strongly considered. Rechallenge of immunotherapy after a kidney irAE, although challenging, is possible and would need careful evaluation on an individual basis.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 50 条
  • [1] Diagnosis, management, and outcomes of immune checkpoint inhibitor induced acute interstitial nephritis: A single-center experience
    Elghawy, Omar
    Patel, Reema
    Barsouk, Adam
    Puthumana, Joe
    Xu, Jason
    Sussman, Jonathan
    Horton, Bethany
    Kaur, Varinder
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [2] SUCCESSFUL TREATMENT OF ACUTE INTERSTITIAL NEPHRITIS INDUCED BY IMMUNE CHECKPOINT INHIBITOR RECHALLENGE
    Hanna, Mark
    Nalluru, Swarna
    Papamarkakis, Kostas
    McCann, John
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S540 - S540
  • [3] Interstitial nephritis in immune checkpoint inhibitor therapy
    Manohar, Sandhya
    Albright, Robert C., Jr.
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 252 - 252
  • [4] Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience
    Oleas, Diana
    Bolufer, Monica
    Agraz, Irene
    Felip, Enriqueta
    Munoz, Eva
    Gabaldon, Alejandra
    Bury, Roxana
    Espinel, Eugenia
    Seron, Daniel
    Garcia-Carro, Clara
    Jose Soler, Maria
    CLINICAL KIDNEY JOURNAL, 2021, 14 (05) : 1364 - 1370
  • [5] RECURRENT ACUTE INTERSTITIAL NEPHRITIS ON RECHALLENGE WITH OMEPRAZOLE
    ASSOUAD, M
    VICKS, SL
    POKROY, MV
    WILLCOURT, RJ
    LANCET, 1994, 344 (8921): : 549 - 549
  • [6] Acute Interstitial Nephritis Following Snake Envenomation: A Single-Center Experience
    Priyamvada, P. S.
    Shankar, Vijay
    Srinivas, B. H.
    Rajesh, N. G.
    Parameswaran, Sreejith
    WILDERNESS & ENVIRONMENTAL MEDICINE, 2016, 27 (02) : 302 - 306
  • [7] Rheumatic Complications of Immune Checkpoint Inhibitor Therapy: A Single Center Experience
    Nasrallah, Mazen
    Mooradian, Meghan
    Miloslavsky, Eli
    Cohen, Justine
    Gainor, Justin
    Lawrence, Donald
    Reynolds, Kerry
    Kohler, Minna
    Sullivan, Ryan
    Schoenfeld, Sara
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [8] A Single Center Experience of Pneumonitis After Immune Checkpoint Inhibitor Therapy
    Heckman, A. J.
    Kwon, M.
    Arunthari, V.
    Lou, Y.
    Manochakian, R.
    Grage, R.
    Rojas, C.
    Patel, N. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
    Baker, Megan L.
    Yamamoto, Yu
    Perazella, Mark A.
    Dizman, Nazli
    Shirali, Anushree C.
    Hafez, Navid
    Weinstein, Jason
    Simonov, Michael
    Testani, Jeffrey M.
    Kluger, Harriet M.
    Cantley, Lloyd G.
    Parikh, Chirag R.
    Wilson, F. Perry
    Moledina, Dennis G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [10] Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis
    Barbir, Elena-Bianca
    Mohan, Arjunmohan
    Koirala, Priscilla
    Gutierrez, Luis E.
    Giesen, Callen D.
    Lieske, John C.
    Herrmann, Sandra M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025, 40 (03) : 602 - 604